Showing results (301-310 of 606) with videos related to

Sort By:
Pageof 61
Pharmacoeconomics - Open|November 7, 2025
Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility AnalysisGijs van de Wetering, Carolyn Owen, Versha Banerji, et al.
Pharmacoeconomics - Open|November 17, 2025
Estimation of Health Utility Values for Eosinophilic Granulomatosis With PolyangiitisBhovina Buguth, Jacqui Bernarde, Daniel Aggio, et al.
Pharmacoeconomics - Open|March 25, 2020
Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology AppraisalAngela Stainthorpe, Nigel Fleeman, Rachel Houten, et al.
Pharmacoeconomics - Open|January 25, 2020
Metabolic Acidosis in Preterm Infants is Associated with a Longer Length of Stay in the Neonatal Intensive Care UnitMarika Paul, Jamie Partridge, Bridget Barrett-Reis, et al.
Pharmacoeconomics - Open|June 2, 2022
Development of the Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ): A New Patient-Reported Outcome (PRO) InstrumentMatthew Reaney, Veleka Allen, Amy J Sehnert, et al.
Pharmacoeconomics - Open|June 22, 2022
Cost of Surgical Care at Public Sector District Hospitals in India: Implications for Universal Health Coverage and Publicly Financed Health Insurance SchemesManinder Pal Singh, Shankar Prinja, Kavitha Rajsekar, et al.
Pharmacoeconomics - Open|January 12, 2021
Psychometric Validation of the Growth Hormone Deficiency-Child Impact Measure (GHD-CIM)Meryl Brod, Michael Højby Rasmussen, Knud Vad, et al.
Pharmacoeconomics - Open|February 15, 2022
Stage-Related Cost of Treatment of Bladder Cancer in BrazilFernando Korkes, Frederico Timóteo, Luiza C B Soledade, et al.
Pharmacoeconomics - Open|February 19, 2022
Feasibility of Deriving Health State Utilities in Mycosis Fungoides Cutaneous T-Cell Lymphoma Using Mapping AlgorithmsMichela Meregaglia, Rosanna Tarricone
Pharmacoeconomics - Open|January 31, 2022
An Economic Evaluation Supported by Qualitative Data About the Patient Concerns Inventory (PCI) versus Standard Treatment Pathway in the Management of Patients with Head and Neck CancerVictory 'Segun Ezeofor, Llinos Haf Spencer, Simon N Rogers, et al.
Pageof 61